Physician profile
Jonathan R Strosberg
NPI 1013960988
$148,013.31
in general payments reported to CMS, 2019-2025
25 companies · $27K in 2025
The $27K reported for 2025 was more than what 91% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $24K · 2021: $28K · 2022: $24K · 2023: $5,185 · 2024: $14K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Honoraria: $8,690 · Food and Beverage: $5,178 · Travel and Lodging: $4,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,159.50 |
| Honoraria | $8,690.00 |
| Food and Beverage | $5,177.86 |
| Travel and Lodging | $4,546.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $54,613.67 | 2019-2025 | Onivyde, Somatuline Depot |
| Advanced Accelerator Applications | $12,936.58 | 2019-2020 | |
| Tersera Therapeutics LLC | $12,661.11 | 2021-2025 | Xermelo |
| Exelixis INC. | $12,122.65 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $8,845.35 | 2025 | |
| Sun Pharmaceutical Industries INC. | $8,800.00 | 2020 | |
| Terumo Medical Corporation | $7,875.00 | 2021-2022 | |
| Boehringer Ingelheim International Gmbh | $6,675.00 | 2022-2023 | |
| Curium US LLC | $5,115.62 | 2024-2025 | Detectnet |
| Genzyme Corporation | $4,206.41 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,115.30 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $3,221.96 | 2019-2020 | |
| Chiasma, INC. | $1,800.00 | 2021 | |
| Delcath Systems | $1,661.18 | 2025 | Hepzato Kit, Hepzato Kit |
| Bard Peripheral Vascular, INC. | $1,300.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $823.37 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $650.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $237.62 | 2022 | |
| Progenics Pharmaceuticals, INC. | $133.51 | 2025 | |
| Amgen INC. | $108.96 | 2025 | |
| Amryt Pharma Holdings Ltd | $81.27 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.75 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Strosberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.